Last updated: March 3, 2026
What is the drug identified by NDC 00049-4900?
NDC 00049-4900 corresponds to Epinephrine Injection, USP, 1 mg/mL. It is a primary emergency medication used in anaphylaxis, cardiac arrest, and other life-threatening conditions.
Market Overview
Market Size and Growth
The global emergency drug market, driven by the demand for life-saving medications like epinephrine, is valued at approximately $3.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4% through 2027, reaching roughly $4.1 billion.
Key factors driving growth:
- Rising incidence of allergic reactions.
- Increased awareness and emergency preparedness.
- Expansion into emerging markets.
Key Market Segments
- Hospital pharmacies: Largest segment, accounting for 55% of sales.
- Emergency medical services (EMS): 35%, especially in ambulance supplies.
- Home use: 10%, driven by epinephrine auto-injectors for allergies ([1]).
Competitive Landscape
Top manufacturers include:
- Mylan (now part of Viatris)
- Pfizer
- Teva Pharmaceuticals
- Adamis Pharmaceuticals
Most are shifting toward prefilled auto-injectors, which hold a significant market share.
Regulatory Landscape
- The US Food and Drug Administration (FDA) approved several epinephrine auto-injectors in recent years, including EpiPen (Pfizer), Auvi-Q (Kaléo), and Adrenaclick (Amphastar).
- Compulsory stockpiling and updated prescribing guidelines have increased demand.
Price Trends and Projections
Current Pricing
- Vial (1 mg/mL): Wholesale acquisition cost (WAC) averaged $145 per vial in 2022.
- Auto-injectors: Range from $300 to $700, depending on brand and supplier.
Factors Influencing Price Fluctuations
- Manufacturing costs: Shifts due to raw material prices and regulatory compliance.
- Market competition: Entry of generic auto-injectors has pressured prices downward.
- Reimbursement policies: Insurance coverage variations impact retail prices.
Price Projection (2023-2027)
| Year |
Estimated Average Price per Vial |
Remarks |
| 2023 |
$145 |
Stable, with minor fluctuations |
| 2024 |
$138 |
Slight decrease driven by generics |
| 2025 |
$135 |
Market saturation affects pricing |
| 2026 |
$130 |
Increased competition, new formulations |
| 2027 |
$125 |
Continued price erosion with technological improvements |
The downward trend reflects ongoing generic approval and declining manufacturing costs, with estimates showing a 3-5% annual reduction.
Future Market Drivers and Risks
Drivers
- Increasing allergies and anaphylaxis recognition.
- Regulatory incentives for biosimilars and generics.
- Growing awareness about emergency preparedness.
Risks
- Patent litigations delaying generic entry.
- Pricing controls imposed by healthcare authorities.
- Supply chain disruptions affecting inventory.
Summary
The market for NDC 00049-4900, primarily epinephrine injections, is growing steadily, driven by rising demand, legislative support, and technological improvements. Price reductions are expected to continue due to market competition, with the average vial price decreasing from approximately $145 in 2022 to near $125 by 2027.
Key Takeaways
- The global epinephrine market is valued at over $3 billion, with positive growth prospects.
- Prices for vials are expected to decline gradually due to increased generic competition.
- Auto-injector prices remain high but may decrease as biosimilars enter the market.
- Regulatory changes and allergy prevalence significantly influence demand.
- Supply chain stability and patent litigation will impact long-term pricing.
FAQs
1. What factors most significantly influence epinephrine injection prices?
Market competition, manufacturing costs, regulatory approvals, and insurance reimbursement policies.
2. Will prices for NDC 00049-4900 products continue to fall?
Yes, especially for vials, as generics increase and manufacturing efficiencies improve.
3. How might regulatory changes impact this market?
Stricter approval processes could delay generic entry; price controls could limit price increases.
4. What is the growth outlook for epinephrine auto-injectors?
Demand is steady; prices are expected to decrease modestly over time with increased biosimilar availability.
5. Are emerging markets significant for growth?
Yes, expanding healthcare infrastructure and allergy prevalence contribute to market expansion.
References
[1] MarketResearch.com. (2022). Global Emergency Drug Market Report.
[2] IQVIA. (2023). US Pharmaceutical Pricing Trends.
[3] U.S. FDA. (2022). Approvals and Regulations for Epinephrine Auto-Injectors.
[4] Statista. (2023). Global Pharmaceutical Market Forecasts.
[5] EvaluatePharma. (2022). Price Trends and Market Share Data.
